Adjuvant therapy in high-risk colon cancer

Seminars in Oncology

Volumn 27, Issue 5 SUPPL. 10, 2000, Pages 48-59

  Bleiberg, H ^a  

^a JULES BORDET INSTITUTE   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

FLUOROURACIL; FOLINIC ACID; IRINOTECAN; LEVAMISOLE; OXALIPLATIN; TOMUDEX;

CANCER ADJUVANT THERAPY; CANCER SURGERY; CANCER SURVIVAL; CLINICAL TRIAL; COLON CARCINOMA; CONFERENCE PAPER; DOSE RESPONSE; DRUG EFFICACY; DRUG MECHANISM; HUMAN; IMMUNOTHERAPY; INTERMETHOD COMPARISON; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; QUALITY OF LIFE; TREATMENT OUTCOME; TREATMENT PLANNING; TUMOR IMMUNITY;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CLINICAL TRIALS; COLONIC NEOPLASMS; COMBINED MODALITY THERAPY; FLUOROURACIL; HUMAN; IMMUNOTHERAPY; LEUCOVORIN; LEVAMISOLE;

EID: 0033790328     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (72)

1. Large bowel cancer The current status of treatment
2. Adjuvant therapy of colorectal cancer. Why we still don't know
3. Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma
4. Efficacy of adjuvant fluorouracil and folinic acid in colon cancer
5. The benefit of leucovorin-modulated fluorouracil as postoperative adjuvant therapy for primary colon cancer: Results from National Surgical Adjuvant Breast and Bowel Project Protocol C-03
6. Folinic acid and 5-fluorouracil as adjuvant chemotherapy in colon cancer
7. Controlled trial of fluorouracil and low-dose leucovorin given for 6 months as postoperative adjuvant therapy for colon cancer
8. Levamisole
9. Fluorouracil plus levamisole as effective adjuvant therapy after resection of stage iii colon carcinoma: A final report
10. Adjuvant therapy for patients with colon and rectal cancer
11. Adjuvant 5FU plus levamisole improves survival in stage II and III colonic cancer, but not in rectal cancer. Interim Analysis of The Netherlands Adjuvant Colorectal Cancer Project (NACCP)
12. Meta-analysis of randomized trials testing the biochemical modulation of fluorouracil by methotrexate in metastatic colorectal cancer
13. Postoperative adjuvant chemotherapy or BCG for colon cancer: Result from NSABP protocol C-01
14. The relative efficacy of 5-FU + leucovorin (FU-LV), 5-FU + levamisole (FU-LEV), and 5-FU + leucovorin + levamisole (FU-LV-LEV) in patients with Dukes' B and C carcinoma of the colon
15. Fluorouracil (FU), leucovorin (LV) and levamisole (LEV) adjuvant therapy for colon cancer: Preliminary results of INT-0089
16. Prospectively randomized trial of postoperative adjuvant chemothetapy in patients with high-risk colon cancer
17. Adjuvant therapy of Dukes' A, B, and C adenocarcinoma of the colon with portal-vein fluorouracil hepatic infusion: Preliminary results of National Surgical Adjuvant Breast and Bowel Project protocol C-02
18. Comparative efficacy of adjuvant chemotherapy in patients with Dukes' B versus Dukes' C colon cancer: Results from four National Surgical Adjuvant Breast and Bowel Project Adjuvant studies (C-01, C-02, C-03, and C-04)
19. Adjuvant portalvein infusion of fluorouracil and heparin in colorectal cancer: A randomised trial
20. Randomized trial of adjuvant perioperative chemotherapy in radically resected colorectal cancer (SAKK 40/87)
21. Intraportal 5FU (PVI) and peri-operative radiotherapy (RT) in the adjuvant treatment of colorectal cancer (CRCa)-3681 patients randomised in the UK Coordinating Committee on Cancer Research (UKCCCR) AXIS Trial
22. Efficacy of adjuvant fluorouracil and folinic acid in B2 colon cancer
23. Event free and overall survival is increased by FUFA in resected B colon cancer: A pooled analysis of five randomized trials (RCTS)
24. Portal vein chemotherapy for colorectal cancer: A recta-analysis of 4000 patients in 10 studies
25. Micrometastases and survival in stage II colorectal cancer
26. Accuracy of diagnosis of micrometastase in colorectal cancer (CRCa) by sentinel lymph (SLN) mapping technique
27. Genetic detection of colorectal cancer cells in circulation and lymph nodes
28. In vivo kinetics of thymidylate synthase inhibition in 5-fluorouracil-sensitive and resistant murine colon adenocarcinomas
29. Fluorouracil and high close leucovorin in previously treated patients with metastatic breast disease
30. Thymidylate synthase: A target enzyme in cancer chemotherapy
31. The role of thymidylate synthase expression in prognosis and outcome of adjuvant chemotherapy in patients with rectal cancer
32. Quantitation of intratumoral thymidylate synthase expression predicts for disseminated colorectal cancer response and resistance to protracted-infusion fluorouracil and weekly leucovorin
33. The cytological demonstration and significance of tumour cells in the mesenteric blood in patients with colorectal cancer
34. Prophylactic treatment of cancer
35. A randomized controlled trial of adiuvant portal vein cytotoxic perfusion in colorectal cancer
36. Mortal vein chemotherapy for colorectal cancer: Meta-analysis of 4000 patients in 10 studies
37. The Will Rogers phenomenon. Stage migration and new diagnostic techniques as a source of misleading statistics for survival in cancer
38. Long-term results of single course of adjuvant intraportal chemotherapy for colorectal cancer
39. A randomized trial of intraportal (IP) versus systemic (SY) versus IP + SY adjuvant chemotherapy in patients (pts) with resected Dukes B-Ccolon carcinoma (CC)
40. Prospective randomised trial of intravenous versus intraperitoneal 5-fluorouracil in patients with advanced primary colon or rectal cancer
41. Peritoneal carcinomatosis from adenocarcinoma of the colon
42. Gastrointestinal malignancy: Rationale for adjuvant therapy using early postoperative intraperitoneal chemotherapy
43. Large scale trial for adiuvant treatment in high risk resected colorectal cancers: Rationale to test the combination of locoregional and systemic chemotherapy and to compare 1-leucovorin + 5-FU to levamisole + 5FU
44. Early post-operative intraperitoneal chemotherapy is feasible and well tolerated in colon cancer. A prospective randomised study
45. Combined intraperitoneal plus intravenous chemotherapy after curative resection for colonic adenocarcinoma
46. Combined intravenous and intraperitoneal chemotherapy with fluorouracil + leucovorin vs fluorouracil + levamisole for adiuvant therapy of resected colon carcinoma
47. The role of immunotherapy in colorectal cancer
48. Biological response modifiers in the treatment of gastrointestinal cancer
49. Immunotherapy by active specific immunization: Basic principles and preclinical studies
50. Adjuvant active specific immunotherapy for human colorectal cancer: 6.5-year median follow-up of a phase III prospectively randomized trial
51. Survival and relapse in adjuvant autologous tumor vaccine therapy for Dukes B and C colon cancer - EST 5283
52. Active specific immunotherapy for stage II and stage III human colon cancer: A randomised trial
53. Controlled clinical trial of adjuvant immunotherapy with BCG and neuraminidase-treated autologous tumour cells in large bowel cancer
54. The therapeutic use of monoclonal antibodies in colorectal carcinoma
55. Antibodies as cytotoxic therapy
56. Tumour-growth suppression in nude mice by a murine monoclonal antibody: Factors hampering successfuf therapy
57. Randomised trial of monoclonal antibody for adjuvant therapy of resected Dukes' C colorectal carcinoma
58. Differential expression of proliferation-associated molecules in individual micrometastatic carcinoma cells
59. Monoclonal antibody therapy for resected Dukes' C colorectal cancer: Seven-year outcome of a multicenter randomized trial
60. Final results of a randomised trial comparing Tomudex (raltitrexed) with 5-fluorouracil plus leucovorin in advanced colorectal cancer
61. Raltitrexed (Tomudex) versus 5-fluorouracil and leucovorin (5-FU +LV) in patients with advanced colorectal cancer (ACC): Results of a randomized multicenter North American trial
62. Results of a European multicentre trial of Tomudex versus 5-FU/high dose LV (Machover regimen)
63. Interferon-alpha does not improve the antineoplastic efficacy of high-dose infusional 5-fluorouracil plus folinic acid in advanced colorectal cancer
64. A review of GERCOD trials of bimonthly leucovorin plus 5-fluorouracil 48-h continuous infusion in advanced colorectal cancer: Evolution of a regimen
65. A phase II study of weekly 48-hour infusions with high-dose fluorouracil in advanced colorectal cancer: An alternative to biochemical modulation
66. Randomized trial comparing monthly low-dose leucovorin and fluorouracil bolus with high-dose 48-hour continuous infusion fluorouracil for advanced colorectal cancer. A Spanish Cooperative Group for Gastrointestinal Tumor Therapy (TTD) study
67. Randomised multicentre trial of chronotherapy with oxaliplatin, fluorouracil, and folinic acid in metastatic colorectal cancer
68. Oxaliplatin combined to 5-fluorouracil and folinic acid: An effective therapy in patients with advanced colorectal cancer
69. Phase III trial of 5-fluorouracil (5-FU), folinic acid (FA), with or without oxaliplatin (OXA) in previously untreated patients (pts) with metastatic colorectal cancer (MCC)
70. A randomised trial of leucovorin (LV) and 5-fluorouracil (5FU) with or without oxaliplatin in advanced colorectal cancer (CRC)
71. A randomized phase III trial comparing irinoteca (IRI) + 5FU/folinic acid (FA) to the same schedule of FU/FA in patients (pts) with metastatic colorectal cancer (MCRC) as front line chemotherapy (CT)
72. Weekly irinotecan (CPT-11), leucovorin (LV), and fluorouracil (FU) is superior to daily X5 LV/FU in patients (PTS) with previously untreated metastatic colorectal cancer (CRC)